Article Details

Federal Court of Appeal remits pricing decision on Alexion's Soliris to Patented Medicine ...

Retrieved on: 2021-09-08 00:00:00

Tags for this article:

Click the tags to see associated articles and topics

Federal Court of Appeal remits pricing decision on Alexion's Soliris to Patented Medicine .... View article details on HISWAI: https://www.lexology.com/commentary/healthcare-life-sciences/canada/smart-biggar/federal-court-of-appeal-remits-pricing-decision-on-alexions-soliris-to-patented-medicine-prices-review-board

Excerpt

In September 2017 the Patented Medicine Prices Review Board (the board) decided that Alexion's Soliris (eculizumab) was sold at an excessive price.

Article found on: www.lexology.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up